Vivek Subbiah: Now we have 3 options for NTRK fusion positive solid tumors
Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, posted on LinkedIn:
“Honored to speak at an interactive Oslo Precision Medicine Round Table panel discussion on the latest in ‘Precision medicine and tumor-agnostic drug development’ at Hotel Continental, Oslo, Norway.
Huge thanks to colleagues from Bristol Myers Squibb Drs. Ali Areffard and Aslaug Muggerud for their organizing the meeting and hospitality.
Congrats on the tumor agnostic EMA authorization of Repotrectinib for NTRK fusion positive tumors.
Now we have 3 options for NTRK fusion positive solid tumors – Larotrectinib, Entrectinib and now Repotrectinib.
Special thanks to Åsmund Flobak for expertly moderating the session and all the insightful questions. The experience was enriched by fantastic food and thought-provoking discussions.”
Åsmund Flobak, Associate Professor at Norwegian University of Science and Technology (NTNU), shared this post on LinkedIn, adding:
“Thank you Vivek for sharing with us so much from your experiences, research and insights, it was inspirational. Looking forward to next time when it comes.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023